The Role of Diagnostic Testing in Irritable Bowel Syndrome

Gastroenterology Clinics of North America

Volumn 40, Issue 1, 2011, Pages 105-119

  Furman, David L ^a   Cash, Brooks D ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Celiac disease; Colonoscopy; Diagnosis; Irritable bowel syndrome; Rome criteria

Indexed keywords

BIOLOGICAL MARKER; GASTROINTESTINAL HORMONE;

ARTICLE; BLOOD ANALYSIS; BREATH ANALYSIS; CELIAC DISEASE; CLINICAL FEATURE; COLONOSCOPY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; FAMILY HISTORY; FECES ANALYSIS; HUMAN; INTESTINE ENDOSCOPY; IRON DEFICIENCY ANEMIA; IRRITABLE COLON; MANNING CRITERIA; PREDICTIVE VALUE; QUESTIONNAIRE; RECTUM HEMORRHAGE; ROME I CRITERIA; ROME II CRITERIA; ROME III CRITERIA; SENSITIVITY AND SPECIFICITY; SEROLOGY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

EID: 79951561277     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.12.001     Document Type: Review

References (66)

1. Longstreth G.F., Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees: prevalence, demographics and clinical correlates. Dig Dis Sci 1993, 38:1581-1589.
2. Mitchell C.M., Drossman D.A. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987, 92:1282-1284.
3. Sandler R.S. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990, 99:409-415.
4. Lacy B.E., Rosemore J., Robertson D., et al. Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol 2006, 41:892-902.
5. Spiegel B.M., Farid M., Esrailian E., et al. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists and IBS experts. Am J Gastroenterol 2010, 105:848-858.
6. Manning A.P., Thompson W.G., Heaton K.W., et al. Towards a positive diagnosis of the irritable bowel syndrome. Br Med J 1978, 2:653-654.
7. Thompson W.G., Dotewall G., Drossman D.A., et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989, 2:92-95.
8. Thompson W.G., Longstreth G.F., Drossman D.A., et al. Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl 2):II43-II47.
9. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130(5):1480-1491.
10. Brandt L.J., Locke R., Olden K., et al. An evidence based approach to the diagnosis of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(Suppl 11):S1-S26.
11. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131.
12. Vanner S.J., Depew W.T., Paterson W.G., et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999, 94:2912-2917.
13. Whitehead W.E., Drossman D.A. Validation of symptom-based diagnostic criteria for IBS: a critical review. Am J Gastroenterol 2010, 105:814-820.
14. Chey W.D., Olden K., Carter E., et al. Utility of the Rome I and Rome II criteria for IBS in US women. Am J Gastroenterol 2002, 97:2803-2811.
15. Drossman D.A. An integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther 1999, 13(Suppl 2):3-14.
16. Camilleri M., Prather C.M. The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med 1992, 116:1001-1008.
17. American Gastroenterological Association American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002, 123:2105-2107.
18. Spiller R.C., Thompson W.G. Bowel disorders. Am J Gastroenterol 2010, 105:775-779.
19. Cash B.D., Schoenfeld P.S., Chey W.D. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002, 97:2812-2819.
20. Brandt L.J., Chey W.D., Foxx-Orenstein A.E., et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104(Suppl 1):S1-S35.
21. Whitehead W.E., Palsson O.S., Feld A.D., et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther 2006, 24:137-146.
22. Hammer J., Eslick G.D., Howell S.C., et al. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004, 53:666-672.
23. Adelstein B.A., Irwig L., Macaskill P., et al. Who needs colonoscopy to identify colorectal cancer? Bowel symptoms do not add substantially to age and other medical history. Aliment Pharmacol Ther 2010, 32:270-281.
24. Lijmer J.G., Mol B.W., Heisterkamp S., et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999, 282:1061-1066.
25. Irwig L., Tostetson A.N., Gastonis C., et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994, 120:667-676.
26. Hamm L.R., Sorrells S.C., Harding J.P., et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol 1999, 94:1279-1282.
27. Tolliver B.A., Herrera J.L., DiPalma J.A. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol 1994, 89:176-178.
28. MacIntosh D.G., Thompson W.G., Patel D.G., et al. Is rectal biopsy necessary in irritable bowel syndrome?. Am J Gastroenterol 1992, 87:1407-1409.
29. Francis C.Y., Duffy J.N., Whorwell P.J., et al. Does routine ultrasound enhance diagnostic accuracy in irritable bowel syndrome?. Am J Gastroenterol 1996, 91:1348-1350.
30. Sanders D.S., Carter M.J., Hurlstone D.P., et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling the ROME II criteria referred to secondary care. Lancet 2001, 358:1504-1508.
31. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
32. Cash B.D., Lee D., Riddle M., et al. Yield of diagnostic testing in patients with suspected irritable bowel syndrome (IBS): a prospective, US multicenter trial. Am J Gastroenterol 2008, 103(Suppl 1):S462. [abstract 1184].
33. Zipser R.D., Patel S., Yahya K.Z., et al. Presentations of adult celiac disease in a nationwide patient support group. Dig Dis Sci 2003, 48:761-764.
34. Fasano A., Berti I., Gerarduzzi T., et al. Prevalence of celiac disease in at-risk and not at-risk groups in the United States. Arch Intern Med 2003, 163:286-292.
35. McFarlane X.A., Bhalla A.K., Roberston D.A. Effect of a gluten-free diet on osteopenia in adults with newly diagnosed coeliac disease. Gut 1996, 39:180-184.
36. West J., Logan R.F., Smith C.J., et al. Malignancy and mortality in people with celiac disease: population based cohort study. BMJ 2004, 329:716-719.
37. Catassi C., Fabiani E., Corrao G., Italian Working Group on Coeliac Disease and Non-Hodgkin's Lymphoma, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002, 287:1413-1419.
38. Marsh M.N. Gluten, major histocompatibility complex, and the small intestine: a molecular and immunobiologic approach to the spectrum of gluten sensitivity. Gastroenterology 1992, 102:330.
39. Ford A.C., Chey W.D., Talley N.J., et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome. Arch Intern Med 2009, 169:651-658.
40. Mein S.M., Ladabaum U. Serological testing for celiac disease in patients with symptoms of irritable bowel syndrome: a cost effectiveness analysis. Aliment Pharmacol Ther 2004, 19:1199-1210.
41. Spiegel B.M., DeRosa V.P., Gralnek I.M., et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004, 126:1721-1732.
42. Talley N.J., Gabriel S.E., Harmsen W.S., et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995, 109:1736-1741.
43. Lieberman D., Holub J., Eisen G., et al. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005, 62:875-883.
44. Akhtar A.J., Shaheen M.A., Zha J. Organic lesions in patients with irritable bowel syndrome. Med Sci Monit 2006, 12:363-367.
45. Chey W.D., Nojkov B., Rubenstein J.H., et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective controlled US trial. Am J Gastroenterol 2010, 105:859-865.
46. Limsui D., Pardi D.S., Camilleri M., et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007, 13:175-181.
47. Chang L., Lee O.Y., Naliboff B., et al. Sensation of bloating and visible distension in patients with irritable bowel syndrome. Am J Gastroenterol 2001, 96:3341-3347.
48. Ringel Y., Williams R.E., Kalliani L., et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009, 7:68-72.
49. Pimentel M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
50. Ford A.C., Spiegel B.M., Talley N.J., et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009, 7:1279-1286.
51. Posserud I., Stotzer P.O., Bjornsson E.S., et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007, 56:802-808.
52. Scrimshaw N.S., Murray A.B. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr 1988, 48:1079-1159.
53. Jackson K.A., Savaiano D.A. Lactose maldigestion, calcium intake and osteoporosis in African-, Asian-, and Hispanic-Americans. J Am Coll Nutr 2001, 20:198s-207s.
54. Vernia P., Di Camillo M., Marinaro V. Lactose malabsorption, irritable bowel syndrome and self-reported milk intolerance. Dig Liver Dis 2001, 33:234-239.
55. Choi Y.K., Kraft N., Zimmerman B., et al. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol 2009, 42:233-238.
56. Law D., Conklin J., Pimentel M. Lactose intolerance and the role of the lactose breath test. Am J Gastroenterol 2010, 105:1726-1728.
57. Suarez F.L., Savaiano D.A., Levitt M.D. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995, 333:1-4.
58. Chey W., Talley N., Lembo A., et al. Rifaximin significantly improves quality of life versus placebo in patients with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2008, 103(Suppl 1):S461-S462.
59. Pimentel M, Lembo A, Chey WD, et al. Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American phase 3 trials (Target 1 and Target 2) [abstract 475i]. Presented at Digestive Disease Week (DDW) 2010 in New Orleans (LA), 2010.
60. Stark D., van Hal S., Marriott D., et al. Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and management. Int J Parasitol 2007, 37:11-20.
61. Sugi K., Saitoh O., Hirata I., et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996, 91:927-934.
62. Kane S.V., Sandborn W.J., Rufo P.A., et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003, 98:1309-1314.
63. Schoepfer A.M., Trummler M., Seeholzer P., et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008, 14:32-39.
64. Langhorst J., Elsenbruch S., Koelzer J., et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP and clinical indices. Am J Gastroenterol 2008, 103:162-169.
65. Poullis A., Foster R., Mendall M.A., et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003, 18:756-762.
66. Lembo A.J., Neri B., Tolley J., et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009, 29:834-842.